CNBC Power Lunch April 28, 2016
Lets bring in michael ye and another health care analyst. Michael, first you to. Given the deals that we have seen, not just today but in the past, why do you believe a biomarine or vertex may be takeout targets down the line . Two reasons. One is if you looked at biotech valuations, theyre down 35 off the top in the last 6 to 8 months on political rhetoric that we talked about. So asset prices have come down and become a lot more attractive. The second point is that theres no change to the fact that Big Companies need commercial products and they need pipeline. Thats exactly what youre seeing...
Source: archive.org
